Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression

Beth M. Tyler, Karen Jansen, Daniel J Mc Cormick, Christopher L. Douglas, Mona Boules, Jennifer A. Stewart, Lihong Zhao, Benjamin Lacy, Bernadette Cusack, Abdul Fauq, Elliott Richelson

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Intraperitoneal injection of an unmodified antisense peptide nucleic acid (PNA) complementary to mRNA of the rat neurotensin (NT) receptor (NTR1) was demonstrated by a gel shift assay to be present in brain, thus indicating that the PNA had in fact crossed the blood-brain barrier. An i.p. injection of this antisense PNA specifically inhibited the hypothermic and antinociceptive activities of NT microinjected into brain. These results were associated with a reduction in binding sites for NT both in brain and the small intestine. Additionally, the sense-NTR1 PNA, targeted to DNA, microinjected directly into the brain specifically reduced mRNA levels by 50% and caused a loss of response to NT. To demonstrate the specificity of changes in behavioral, binding, and mRNA studies, animals treated with NTR1 PNA were tested for behavioral responses to morphine and their mu receptor levels were determined. Both were found to be unaffected in these NTR1 PNA- treated animals. The effects of both the antisense and sense PNAs were completely reversible. This work provides evidence that any antisense strategy targeted to brain proteins can work through i.p. delivery by crossing the normal blood-brain barrier. Equally important was that an antigene strategy, the sense PNA, was shown in vivo to be a potentially effective therapeutic treatment.

Original languageEnglish (US)
Pages (from-to)7053-7058
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume96
Issue number12
DOIs
StatePublished - Jun 8 1999

Fingerprint

Neurotensin Receptors
Peptide Nucleic Acids
Blood-Brain Barrier
Gene Expression
Neurotensin
Brain
Messenger RNA
mu Opioid Receptor
Intraperitoneal Injections
Morphine
Small Intestine
Gels
Binding Sites
Injections
DNA
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. / Tyler, Beth M.; Jansen, Karen; Mc Cormick, Daniel J; Douglas, Christopher L.; Boules, Mona; Stewart, Jennifer A.; Zhao, Lihong; Lacy, Benjamin; Cusack, Bernadette; Fauq, Abdul; Richelson, Elliott.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, No. 12, 08.06.1999, p. 7053-7058.

Research output: Contribution to journalArticle

Tyler, Beth M. ; Jansen, Karen ; Mc Cormick, Daniel J ; Douglas, Christopher L. ; Boules, Mona ; Stewart, Jennifer A. ; Zhao, Lihong ; Lacy, Benjamin ; Cusack, Bernadette ; Fauq, Abdul ; Richelson, Elliott. / Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. In: Proceedings of the National Academy of Sciences of the United States of America. 1999 ; Vol. 96, No. 12. pp. 7053-7058.
@article{0260bce74cb845b085ddc601230e95cf,
title = "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression",
abstract = "Intraperitoneal injection of an unmodified antisense peptide nucleic acid (PNA) complementary to mRNA of the rat neurotensin (NT) receptor (NTR1) was demonstrated by a gel shift assay to be present in brain, thus indicating that the PNA had in fact crossed the blood-brain barrier. An i.p. injection of this antisense PNA specifically inhibited the hypothermic and antinociceptive activities of NT microinjected into brain. These results were associated with a reduction in binding sites for NT both in brain and the small intestine. Additionally, the sense-NTR1 PNA, targeted to DNA, microinjected directly into the brain specifically reduced mRNA levels by 50{\%} and caused a loss of response to NT. To demonstrate the specificity of changes in behavioral, binding, and mRNA studies, animals treated with NTR1 PNA were tested for behavioral responses to morphine and their mu receptor levels were determined. Both were found to be unaffected in these NTR1 PNA- treated animals. The effects of both the antisense and sense PNAs were completely reversible. This work provides evidence that any antisense strategy targeted to brain proteins can work through i.p. delivery by crossing the normal blood-brain barrier. Equally important was that an antigene strategy, the sense PNA, was shown in vivo to be a potentially effective therapeutic treatment.",
author = "Tyler, {Beth M.} and Karen Jansen and {Mc Cormick}, {Daniel J} and Douglas, {Christopher L.} and Mona Boules and Stewart, {Jennifer A.} and Lihong Zhao and Benjamin Lacy and Bernadette Cusack and Abdul Fauq and Elliott Richelson",
year = "1999",
month = "6",
day = "8",
doi = "10.1073/pnas.96.12.7053",
language = "English (US)",
volume = "96",
pages = "7053--7058",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "12",

}

TY - JOUR

T1 - Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression

AU - Tyler, Beth M.

AU - Jansen, Karen

AU - Mc Cormick, Daniel J

AU - Douglas, Christopher L.

AU - Boules, Mona

AU - Stewart, Jennifer A.

AU - Zhao, Lihong

AU - Lacy, Benjamin

AU - Cusack, Bernadette

AU - Fauq, Abdul

AU - Richelson, Elliott

PY - 1999/6/8

Y1 - 1999/6/8

N2 - Intraperitoneal injection of an unmodified antisense peptide nucleic acid (PNA) complementary to mRNA of the rat neurotensin (NT) receptor (NTR1) was demonstrated by a gel shift assay to be present in brain, thus indicating that the PNA had in fact crossed the blood-brain barrier. An i.p. injection of this antisense PNA specifically inhibited the hypothermic and antinociceptive activities of NT microinjected into brain. These results were associated with a reduction in binding sites for NT both in brain and the small intestine. Additionally, the sense-NTR1 PNA, targeted to DNA, microinjected directly into the brain specifically reduced mRNA levels by 50% and caused a loss of response to NT. To demonstrate the specificity of changes in behavioral, binding, and mRNA studies, animals treated with NTR1 PNA were tested for behavioral responses to morphine and their mu receptor levels were determined. Both were found to be unaffected in these NTR1 PNA- treated animals. The effects of both the antisense and sense PNAs were completely reversible. This work provides evidence that any antisense strategy targeted to brain proteins can work through i.p. delivery by crossing the normal blood-brain barrier. Equally important was that an antigene strategy, the sense PNA, was shown in vivo to be a potentially effective therapeutic treatment.

AB - Intraperitoneal injection of an unmodified antisense peptide nucleic acid (PNA) complementary to mRNA of the rat neurotensin (NT) receptor (NTR1) was demonstrated by a gel shift assay to be present in brain, thus indicating that the PNA had in fact crossed the blood-brain barrier. An i.p. injection of this antisense PNA specifically inhibited the hypothermic and antinociceptive activities of NT microinjected into brain. These results were associated with a reduction in binding sites for NT both in brain and the small intestine. Additionally, the sense-NTR1 PNA, targeted to DNA, microinjected directly into the brain specifically reduced mRNA levels by 50% and caused a loss of response to NT. To demonstrate the specificity of changes in behavioral, binding, and mRNA studies, animals treated with NTR1 PNA were tested for behavioral responses to morphine and their mu receptor levels were determined. Both were found to be unaffected in these NTR1 PNA- treated animals. The effects of both the antisense and sense PNAs were completely reversible. This work provides evidence that any antisense strategy targeted to brain proteins can work through i.p. delivery by crossing the normal blood-brain barrier. Equally important was that an antigene strategy, the sense PNA, was shown in vivo to be a potentially effective therapeutic treatment.

UR - http://www.scopus.com/inward/record.url?scp=13044266375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13044266375&partnerID=8YFLogxK

U2 - 10.1073/pnas.96.12.7053

DO - 10.1073/pnas.96.12.7053

M3 - Article

VL - 96

SP - 7053

EP - 7058

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 12

ER -